Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study

Archive ouverte

Gaujoux, Sébastien | Martin, Guillaume | Mirallié, Eric | Regenet, Nicolas | Le Bras, Maëlle | Pattou, François | Carnaille, Bruno | Cardot-Bauters, Catherine | Groussin, Lionel | Faron, Matthieu | Chanson, Philippe | Najah, Haythem | Tabarin, Antoine | Sauvanet, Alain | Ruszniewski, Philippe | Lifante, Jean Christophe | Walter, Thomas | Carrère, Nicolas | Caron, Philippe | Deguelte, Sophie | Delemer, Brigitte | Binquet, Christine | Jannot, Anne Sophie | Goudet, Pierre

Edité par CCSD ; Wiley -

International audience. Abstract Background The overall natural history, risk of death and surgical burden of patients with multiple endocrine neoplasia type 1 (MEN1) is not well known. Methods Patients with MEN1 from a nationwide cohort were included. The survival of patients with MEN1 was compared with that of the general population using simulated controls. The cumulative probabilities of MEN1-specific operations and postoperative mortality were assessed, and surgical sequences were analysed using sunburst charts and Venn diagrams. Results A total of 1386 patients with MEN1 were included. Life expectancy was significantly reduced in patients with MEN1 compared with simulated controls from the general population, with a lifetime difference of 15 years. Mutations affecting the JunD interaction domain had a significant negative impact on survival. Survival for patients with MEN1 compared with the general population improved over time. The probability of experiencing at least one specific MEN1 operation was above 95 per cent after 75 years, and most patients had surgery at least twice during their lifetime. Time to a 50 per cent risk of MEN1 surgery was 30.5 years for patients born after 1960, compared with 47.9 years for those born before 1960. Sex and mutations affecting the JunD interacting domain had no impact on time to first surgery. There was considerable heterogeneity in surgical sequences, with no specific clinical pathway.Conclusion Life expectancy was significantly lower among patients with MEN1 compared with the general population, and further decreased in patients with mutations affecting the JunD interacting domain. Almost all patients underwent at least one MEN1-specific operation during their lifetime, but there was no standardized sequence of surgery.

Consulter en ligne

Suggestions

Du même auteur

Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1

Archive ouverte | Vinault, Sandrine | CCSD

IF 9.203. International audience. Objective: To assess the distant metastatic potential of duodeno-pancreatic neuroendocrine tumors (DP-NETs) in patients with MEN1, according to functional status and size.Summary Ba...

French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1

Archive ouverte | Goudet, Pierre | CCSD

International audience

Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

Archive ouverte | Thevenon, Julien | CCSD

International audience. Multiple endocrine neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumo...

Chargement des enrichissements...